19 November 2026
Scancell Holdings plc
(“Scancell”, the “Company” or the “Group”)
Result of Annual General Meeting
Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope® active immunotherapies to treat cancer, announces that all resolutions proposed at the Annual General Meeting held today were duly passed.
-ENDS-
Scancell (LSE:SCLP; www.scancell.co.uk) is a late-stage clinical biotechnology company developing targeted, off-the-shelf, active immunotherapies, generated by the ImmunoBody® and Moditope® platforms, designed to stimulate durable anti-tumor responses. The lead product, inzitagene plasmivec, is a DNA ImmunoBody® that has demonstrated a favorable safety profile and clinically meaningful activity both as a monotherapy, in a Phase 1 trial, and in combination with checkpoint therapies in a Phase 2 trial in patients with melanoma. Modi-1 is a Moditope peptide currently being evaluated in a Phase 2 study in head & neck and renal cancers. In addition, Scancell is advancing a pipeline of high affinity GlyMab® antibodies targeting tumor specific glycans, two of which have been licensed for further development to Genmab A/S, an international biotechnology company and global leader in the antibody therapeutics space.
For more information please contact:
|
|
|
|
Scancell Holdings plc |
|
|
Phil L’Huillier, CEO |
|
|
|
|
|
Panmure Liberum (Nominated Adviser and Joint Broker) |
+44 (0) 20 7886 2500 |
|
Emma Earl, Will Goode, Mark Rogers
|
|
|
WG Partners LLP (Joint Broker) Claes Spang |
+44 (0) 20 3705 9330
|
|
|
|
|
Investor and media relations Mandeep Sehmi |
mandeepsehmi@scancell.co.uk |
|
|
|